Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑driven airway constriction, while salbutamol activates β2‑adrenergic receptors, raising intracellular cAMP and relaxing smooth muscle. Together they produce a synergistic bronchodilatory effect that improves airflow more effectively than either agent alone.

The specific dose and frequency of Ipramol Steri-Neb are determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for Ipramol Steri-Neb in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against any possible risks and consider alternative treatments if appropriate. Pregnant or nursing patients should discuss use with their healthcare provider.

To request Ipramol Steri-Neb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the dual‑action formulation of ipratropium bromide and salbutamol offers broader bronchodilation by targeting two complementary pathways. This can result in faster symptom relief and improved lung function, especially in patients who do not achieve adequate control with a single bronchodilator.

Ipramol Steri-Neb should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency.

The medication is delivered via inhalation using a nebulizer or compatible inhalation device. Patients should follow the prescribed technique, ensuring the device is cleaned according to the manufacturer’s instructions to achieve optimal drug delivery.

Serious adverse events include paradoxical bronchospasm, cardiac arrhythmias, severe allergic reactions (including anaphylaxis), and angioedema. Patients should seek immediate medical attention if they experience sudden worsening of breathing, chest pain, rapid heartbeat, swelling of the face or throat, or any signs of an allergic reaction.

Ipramol Steri-Neb is contraindicated in individuals with known hypersensitivity to ipratropium bromide, salbutamol, or any excipients in the formulation. Caution is advised for patients with severe cardiac disease, uncontrolled hypertension, or narrow‑angle glaucoma, and it should be avoided in those using non‑selective β‑blockers.